



# AGENTIC REASONING SCIENTIST

Chrysis Andreou  
Mariam SaadAllah  
Michalis Chrysostomou  
Mohamad Fatfat

# New Mission Statement

- Revolutionize scientific research with a self-improving AI scientist
- Use adaptive, multi-agent reasoning & continuous learning
- Modular design with specialized agents (idea generation, hypothesis, experiment planning, code execution, benchmarking, review) managed by a top-level Manager Agent with meta-reasoning and reinforcement learning.
- Enable flexible human oversight for expert guidance

## Business Model Canvas Highlights

- **Platform:** AI-driven discovery via multi-agent reinforcement learning
- **Partners & Activities:** Collaborations with academia, tech providers, regulators, and industry; focus on R&D, integration, and compliance
- **Value & Outcome:** Faster discovery, rigorous insights, cost efficiency, and a scalable AI solution

## Mission Statement Changes

### From Literature Review:

- Shift to a decentralized, multi-agent system
- Embrace continuous improvement via reinforcement learning
- Increase autonomy with adaptable expert oversight
- Transition to dynamic, independently optimizing agents
- Focus on scalable, advanced AI frameworks

### BMC Rationale:

- Align mission with an AI-driven, scalable business model
- Support faster, cost-efficient research matching market needs
- Enhance system flexibility to serve diverse research and industry partners
- Optimize value delivery through innovative, adaptive processes

# Market Analysis & Beachhead Selection

All markets need fast work and clear results. Each market has its own focus:

- **Academic & Research Institutions (Rank 1)**

**Focus:** Speed up research and boost teamwork.

**Pros:** Trusted, high impact, mission-aligned, and speeds up research and publishing.

**Cons:** Lower economic benefit per user.

- **Private R&D Organizations (Rank 2)**

**Focus:** Fast innovation and quick decisions.

**Pros:** Easy to reach and fits well with innovative work.

**Cons:** Offers less economic benefit than pharma/biotech.

- **Pharma & Biotech Institutions (Rank 3)**

**Focus:** Safe, compliant tools to cut R&D time and costs.

**Pros:** High economic potential and speeds up drug development.

**Cons:** Long sales process and strict rules.

- **Government & Public Research Agencies (Rank 4)**

**Focus:** Secure systems that meet strict rules.

**Pros:** High economic potential and speeds up drug development.

**Cons:** Slow, bureaucratic process and needs full product integration.

- **Conclusion:**

Academic & Research Institutions are our best starting point due to their strong research impact and close match with our goals.

# End-User Profile Definition

- **Demographics:**

- Academics (Professors, Researchers, etc.) with advanced degrees
- Ages 25–65 (31% <45, 39% 45–54, 30% 55+)
- Global reach (concentrated in North America, Europe, Asia)
- Moderate salaries + research grants

- **Psychographics:**

- **Aspirations:** Breakthrough discoveries, top publications, competitive funding
- **Fears:** Falling behind, inaccuracies, delays
- **Motivators & Values:** Recognition, innovation, scientific transparency, collaboration

- **Proxy Products & Engagement:**

- **Tools:** Research managers (EndNote, Zotero), analysis software (MATLAB, R, Python)
- **Platforms:** Google Scholar, ResearchGate, academic conferences, online communities

- **Daily Routine & Priorities:**

- **Day:** Morning research updates, mid-day meetings/literature reviews, afternoon brainstorming
- **Priorities:** Faster discovery (30%), AI-assisted analysis (25%), data management(20%),collaboration (15%), career/funding (10%)





**THANK  
YOU**